Exacerbation Burden in COPD and Occurrence of Mortality in a Cohort of Italian Patients: Results of the Gulp Study

References

• Viegi G, Pistelli F, Sherrill DL, et al. Definition, epidemiology and natural history of COPD. Eur Respir J. 2007;30(5):993–1013. doi:10.1183/09031936.00082507
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2022. Available from: https://goldcopd.org/2022-gold-reports-2/. Accessed October 12, 2022.
   Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–2128. doi:10.1016/S0140-6736(12)61728-0
   PubMed Web of Science ®Google Scholar
• McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365(17):1567–1575. doi:10.1056/NEJMoa1106955
   PubMed Web of Science ®Google Scholar
• Radovanovic D, Contoli M, Braido F, et al. Future perspectives of revaluating mild COPD. Respiration. 2022;101(7):688–696. doi:10.1159/000524102
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Loukides S, Gourgoulianis KI, et al. Global assessment of the COPD patient: time to look beyond FEV1? Respir Med. 2009;103(5):650–660. doi:10.1016/j.rmed.2009.01.001
   PubMed Web of Science ®Google Scholar
• Casanova C, de Torres JP, Aguirre-Jaime A, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med. 2011;184(9):1015–1021. doi:10.1164/rccm.201105-0831OC
   PubMed Web of Science ®Google Scholar
• Han MK, Wise R, Mumford J, et al. Prevalence and clinical correlates of bronchoreversibility in severe emphysema. Eur Respir J. 2010;35(5):1048–1056. doi:10.1183/09031936.00052509
   PubMed Web of Science ®Google Scholar
• Whittaker H, Rubino A, Mullerova H, et al. Frequency and severity of exacerbations of COPD associated with future risk of exacerbations and mortality: a UK routine health care data study. Int J Chron Obstruct Pulmon Dis. 2022;17:427–437. doi:10.2147/COPD.S346591
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Radovanovic D, Contoli M, Di Marco F, et al. Clinical and functional characteristics of COPD patients across gold classifications: results of a multicenter observational study. COPD. 2019;16(3–4):215–226. doi:10.1080/15412555.2019.1659760
   PubMedGoogle Scholar
• Alqahtani JS, Aquilina J, Bafadhel M, et al. Research priorities for exacerbations of COPD. Lancet Respir Med. 2021;9(8):824–826. doi:10.1016/S2213-2600(21)00227-7
   PubMed Web of Science ®Google Scholar
• Celli BR, Decramer M, Wedzicha JA, et al. An official American thoracic society/European respiratory society statement: research questions in COPD. Eur Respir J. 2015;45(4):879–905. doi:10.1183/09031936.00009015
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091–1097. doi:10.1378/chest.09-2029
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963. doi:10.1136/thoraxjnl-2011-201518
   PubMed Web of Science ®Google Scholar
• Hesse K, Bourke S, Steer J. Heart failure in patients with COPD exacerbations: looking below the tip of the iceberg. Respir Med. 2022;196:106800. doi:10.1016/j.rmed.2022.106800
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Criner GJ, Halpin DMG, et al. Time-dependent risk of cardiovascular events following an exacerbation in patients with chronic obstructive pulmonary disease: post hoc analysis from the IMPACT trial. J Am Heart Assoc. 2022;11(18):e024350. doi:10.1161/JAHA.121.024350
   PubMed Web of Science ®Google Scholar
• Halpin DM, Miravitlles M, Metzdorf N, et al. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017;12:2891–2908. doi:10.2147/COPD.S139470
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–1303. doi:10.1136/bmj.320.7245.1297
   PubMed Web of Science ®Google Scholar
• Calverley PM, Wedzicha JA. Chronic obstructive pulmonary disease past, present and future. Thorax. 2007;62(12):1026–1027. doi:10.1136/thx.2007.092635
   PubMed Web of Science ®Google Scholar
• Ferrante G, Baldissera S, Campostrini S. Epidemiology of chronic respiratory diseases and associated factors in the adult Italian population. Eur J Public Health. 2017;27(6):1110–1116. doi:10.1093/eurpub/ckx109
   PubMed Web of Science ®Google Scholar
• Lupi L. Prevalenza della broncopneumopatia cronica ostruttiva e pattern di utilizzo vaccino antinfluenzale nei pazienti assistititi dalla Medicina Generale Italiana. Newsletter Health Search Istituto di Ricerca della S.I.M.G. (Società Italiana di Medicina Generale e delle Cure Primarie), 2020. Available from: https://www.healthsearch.it/documenti/documenti_ricercatori/Newsletter/2020/1_2020.pdf. Accessed October 20, 2022.
   Google Scholar
• Dal negro RW. COPD: the annual cost-of-illness during the last two decades in Italy, and its mortality predictivity power. Healthcare. 2019;7(1):35. doi:10.3390/healthcare7010035
   Web of Science ®Google Scholar
• Strategia globale per la diagnosi, il trattamento e la prevenzione della broncopneumopatia cronica ostruttiva 2015; 2015. https://goldcopd.it/wpcontent/uploads/materiali/2015/GOLD_workshop_report_2015.pdf. Accessed October 20, 2022.
   Google Scholar
• Strategia globale per la diagnosi, il trattamento e la prevenzione della broncopneumopatia cronica ostruttiva 2016; 2016. https://goldcopd.it/wpcontent/uploads/materiali/2016/GOLD_workshop_report_2016.pdf. Accessed October 20, 2022.
   Google Scholar
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2017; 2017. https://goldcopd.org/wp-content/uploads/2017/02/wms-GOLD-2017-FINAL.pdf. Accessed October 20, 2022.
   Google Scholar
• Pistolesi M, Camiciottoli G, Paoletti M, et al. Identification of a predominant COPD phenotype in clinical practice. Respir Med. 2008;102(3):367–376. doi:10.1016/j.rmed.2007.10.019
   PubMed Web of Science ®Google Scholar
• Clinical Identification of Phenotypes in COPD. CLIP COPD 2022; 2022. http://www.clipcopd.com/. Accessed October 20, 2022.
   Google Scholar
• Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41:46s–53s. doi:10.1183/09031936.03.00078002
   PubMedGoogle Scholar
• Witt LJ, Wroblewski KE, Pinto JM, et al. Beyond the lung: geriatric conditions afflict community-dwelling older adults with self-reported chronic obstructive pulmonary disease. Front Med Lausanne. 2022;9:814606. doi:10.3389/fmed.2022.814606
   PubMed Web of Science ®Google Scholar
• Solidoro P, Albera C, Ribolla F, et al. Triple therapy in COPD: can we welcome the reduction in cardiovascular risk and mortality? Front Med Lausanne. 2022;9:816843. doi:10.3389/fmed.2022.816843
   PubMed Web of Science ®Google Scholar
• Calzetta L, Cazzola M, Matera MG, et al. Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple combination therapy in COPD. Chest. 2019;155(4):758–770. doi:10.1016/j.chest.2018.12.016
   PubMed Web of Science ®Google Scholar
• Lai CC, Chen CH, Chen KH, et al. The impact of 52-week single inhaler device triple therapy versus dual therapy on the mortality of COPD patients: a systematic review and meta-analysis of randomized controlled trials. Life. 2022;12(2):173. doi:10.3390/life12020173
   PubMedGoogle Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa1916046
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ritondo BL, Laitano R, Chetta A, Calzetta L. Advances in understanding of mechanisms related to increased cardiovascular risk in COPD. Expert Rev Respir Med. 2021;15(1):59–70. doi:10.1080/17476348.2021.1840982
   PubMed Web of Science ®Google Scholar
• Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013;1(1):73–83. doi:10.1016/S2213-2600(12)70060-7
   PubMed Web of Science ®Google Scholar